Exploratory study for SGLT2 inhibitor -Glucose lowering action, influences of dietary habits/exercise habits on therapeutic effects, and treatment satisfaction
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 26 May 2017
At a glance
- Drugs Canagliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms Canak
- 23 May 2017 Status changed from recruiting to active, no longer recruiting.
- 10 Nov 2015 Status changed from not yet recruiting to recruiting as reported by University Hospital Medical Information Network - Japan record.
- 02 Apr 2015 New trial record